{
  "id": "5c73ad367c78d69471000099",
  "type": "factoid",
  "question": "Which molecule is targeted by Olaratumab?",
  "ideal_answer": "Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1). It is used for treatment of soft tissue sarcoma.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27291997",
    "http://www.ncbi.nlm.nih.gov/pubmed/29413687",
    "http://www.ncbi.nlm.nih.gov/pubmed/29191969",
    "http://www.ncbi.nlm.nih.gov/pubmed/29497315",
    "http://www.ncbi.nlm.nih.gov/pubmed/30406840",
    "http://www.ncbi.nlm.nih.gov/pubmed/28778132",
    "http://www.ncbi.nlm.nih.gov/pubmed/24816152",
    "http://www.ncbi.nlm.nih.gov/pubmed/28620891",
    "http://www.ncbi.nlm.nih.gov/pubmed/30353601",
    "http://www.ncbi.nlm.nih.gov/pubmed/24452395",
    "http://www.ncbi.nlm.nih.gov/pubmed/29478115",
    "http://www.ncbi.nlm.nih.gov/pubmed/28838379",
    "http://www.ncbi.nlm.nih.gov/pubmed/27995580",
    "http://www.ncbi.nlm.nih.gov/pubmed/28745071",
    "http://www.ncbi.nlm.nih.gov/pubmed/28447475",
    "http://www.ncbi.nlm.nih.gov/pubmed/28691538",
    "http://www.ncbi.nlm.nih.gov/pubmed/30513001",
    "http://www.ncbi.nlm.nih.gov/pubmed/28734947",
    "http://www.ncbi.nlm.nih.gov/pubmed/28917265",
    "http://www.ncbi.nlm.nih.gov/pubmed/28187274",
    "http://www.ncbi.nlm.nih.gov/pubmed/29263653"
  ],
  "snippets": [
    {
      "text": "Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFR\u03b1 Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28620891",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES: Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28620891",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusions: Overall, these data indicate that olaratumab, alone and in combination with standard of care, blocks the growth of some preclinical PDGFR\u03b1-expressing pediatric bone and soft tissue tumor models. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29191969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent randomised phase II trial data have indicated that the addition of olaratumab, a novel monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFR\u03b1), to doxorubicin confers an unprecedented improvement in overall survival to patients with anthracycline-na\u00efve advanced soft tissue sarcoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29413687",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "While preclinical data show that olaratumab specifically inhibits PDGFR\u03b1-mediated oncogenic signalling with attendant anti-tumour effects, a lack of correlation between pharmacodynamics markers of PDGFR\u03b1 inhibition and clinical benefit from olaratumab suggest other mechanisms beyond modulation of downstream PDGFR\u03b1 molecular pathways.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29413687",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lartruvo\u00ae (olaratumab) is a fully human immunoglobulin G subclass 1 (IgG1) monoclonal antibody that inhibits platelet-derived growth factor receptor alpha (PDGFR\u03b1). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29497315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab (Lartruvo\u2122) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) receptor \u03b1 (PDGFR\u03b1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27995580",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab acts by selectively binding PDGFR\u03b1, thereby blocking PDGF ligand binding and inhibiting PDGFR\u03b1 activation and downstream signalling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27995580",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab is a human antiplatelet-derived growth factor receptor \u03b1 monoclonal antibody that has antitumour activity in human sarcoma xenografts.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27291997",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE\nOlaratumab is a recombinant human IgG1 monoclonal antibody against PGDFR\u03b1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30406840",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, inhibition of platelet-derived growth factor receptor (PDGFR)-\u03b1 by the monoclonal antibody olaratumab showed promising clinical activity.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28917265",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab (IMC-3G3) is a fully human anti-PDGFR\u03b1 monoclonal antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28838379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab is a humanized IgG1 monoclonal antibody that blocks the platelet-derived growth factor receptor alpha (PDGFR\u03b1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28447475",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lartruvo\u00ae (olaratumab) is a fully human immunoglobulin G subclass 1 (IgG1) monoclonal antibody that inhibits platelet-derived growth factor receptor alpha (PDGFR\u03b1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29497315",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24816152",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab is a fully human IgG1-type anti-PDGFR-\u03b1 monoclonal antibody with a high affinity and a low 50% inhibitory concentration (IC50).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28691538",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab (IMC-3G3) is a fully human monoclonal antibody that selectively binds human PDGFR\u03b1 and blocks ligand binding.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24452395",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab is a fully human IgG1 monoclonal antibody that binds to platelet-derived growth factor receptor \u03b1 (PDGFR-\u03b1) preventing binding of its ligands and receptor activation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29263653",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "BACKGROUND AND OBJECTIVES Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28620891",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab, a monoclonal antibody targeting human platelet-derived growth factor receptor \u03b1, plus doxorubicin significantly improved overall survival in patients with advanced soft-tissue sarcoma (STS) in a prior phase 1b/2 randomized trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30353601",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab (LY3012207/IMC-3G3) is a human mAb that exclusively binds to PDGFR\u03b1 and recently received accelerated FDA approval and conditional EMA approval for treatment of advanced adult sarcoma patients in combination with doxorubicin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29191969",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The most important is the combination of the standard cytotoxic agent doxorubicin plus the platelet-derived growth factor receptor (PDGFR) inhibitor olaratumab, although definitive results from a phase III trial are expected.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30513001",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "DATA SYNTHESIS Olaratumab is a human antiplatelet-derived growth factor receptor \u03b1 monoclonal antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28778132",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lartruvo (olaratumab) is a monoclonal antibody against the extracellular domain of PDGFRA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28187274",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Using phospho-specific antibodies, we show that olaratumab attenuates PDGFR\u03b1 activation in response to PDGF-BB, and reduced phosphorylation of extracellular signal-regulated kinase 1 and 2, Elk-1, p38, Akt, focal adhesion kinase, mechanistic target of rapamycin, C10 regulator of kinase II, and C10 regulator of kinase-like, suggesting that PDGFR\u03b1 contributes to mitogenesis and actin reorganization through diverse downstream effectors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28734947",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab (IMC-3G3) is a fully human anti-PDGFR\u03b1 monoclonal antibody. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28838379",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "<AbstractText Label=\"DATA SYNTHESIS\" NlmCategory=\"RESULTS\">Olaratumab is a human antiplatelet-derived growth factor receptor \u03b1 monoclonal antibody. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28778132",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab: First Global Approval.Olaratumab (Lartruvo\u2122) is a fully human IgG1 monoclonal antibody targeted against the human platelet-derived growth factor (PDGF) receptor \u03b1 (PDGFR\u03b1). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27995580",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Olaratumab is a human antiplatelet-derived growth factor receptor \u03b1 monoclonal antibody that has antitumour activity in human sarcoma xenografts. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27291997",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Olaratumab acts by selectively binding PDGFR\u03b1, thereby blocking PDGF ligand binding and inhibiting PDGFR\u03b1 activation and downstream signalling. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27995580",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase I study of olaratumab in Japanese patients with advanced solid tumors.Olaratumab (IMC-3G3) is a fully human IgG1 monoclonal antibody that selectively binds the external domain of human platelet-derived growth factor receptor-\u03b1 with high affinity and blocks ligand binding. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24816152",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFR\u03b1 Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.<AbstractText Label=\"BACKGROUND AND OBJECTIVES\">Olaratumab is a recombinant human monoclonal antibody that binds to platelet-derived growth factor receptor-\u03b1 (PDGFR\u03b1). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28620891",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "A Phase Ib/randomized Phase II trial of doxorubicin with or without the monoclonal antibody to PDGFR-\u03b1, olaratumab, demonstrated a significant difference in median overall survival in favor of the olaratumab arm.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28745071",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "platelet-derived growth factor receptor-\u03b1"
}